1. BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells.
- Author
-
Zhang X, Liu Y, Dai L, Shi G, Deng J, Luo Q, Xie Q, Cheng L, Li C, Lin Y, Wang Q, Fan P, Zhang H, Su X, Zhang S, Yang Y, Hu X, Gong Q, Yu D, Zheng L, and Deng H
- Subjects
- Adult, Aged, Animals, Benzylamines pharmacology, Cell Line, Tumor, Cell Migration Inhibition genetics, Cyclams pharmacology, Female, Gene Expression Regulation, Neoplastic drug effects, Glioblastoma blood, Glioblastoma pathology, Heterografts, Humans, Male, Mice, Middle Aged, Myeloid-Derived Suppressor Cells metabolism, Myeloid-Derived Suppressor Cells pathology, Neoplasm Staging, Signal Transduction drug effects, Tumor Microenvironment drug effects, Young Adult, Basic-Leucine Zipper Transcription Factors genetics, Chemokine CXCL12 genetics, Glioblastoma genetics, Receptors, CXCR4 genetics, Tumor Suppressor Proteins genetics
- Abstract
The basic leucine zipper ATF-like transcription factor 2 (BATF2) has been implicated in inflammatory responses and anti-tumour effects. Little, however, is known regarding its extracellular role in maintaining a non-supportive cancer microenvironment. Here, we show that BATF2 inhibits glioma growth and myeloid-derived suppressor cells (MDSCs) recruitment. Interestingly, extracellular vesicles (EVs) from BATF2-overexpressing glioma cell lines (BATF2-EVs) inhibited MDSCs chemotaxis in vitro. Moreover, BATF2 inhibited intracellular SDF-1α and contributes to decreased SDF-1α in EVs. In addition, BATF2 downregulation-induced MDSCs recruitment were reversed by blocking SDF-1α/CXCR4 signalling upon AMD3100 treatment. Specifically, detection of EVs in 24 pairs of gliomas and healthy donors at different stages revealed that the abundance of BATF2-positive EVs in plasma (BATF2
+ plEVs) can distinguish stage III-IV glioma from stage I-II glioma and healthy donors. Taken together, our study identified novel regulatory functions of BATF2 in regulating MDSCs recruitment, providing a prognostic value in terms of the number of BATF2+ plEVs in glioma stage.- Published
- 2021
- Full Text
- View/download PDF